Latest Phase III Study Data for Insomnia New Drug Daridorexant

Insomnia is a symptom that does not go to sleep naturallyIt may be difficult to fall asleep (difficult to fall asleep) or it may be difficult to maintain a long period of deep sleep (difficult to maintain sleep)Insomnia is usually accompanied by symptoms such as daytime depression, drowsiness, irritability, or depressionpharmaceutical company Idorsia announced today that a Phase III study of daridorexant treating 924 adult and elderly insomniac patients showed that higher doses of the experimental bixin receptor antagonist daridorexant significantly improved sleep maintenance and total sleep timeThe company reported in April that daridorexant improved overall sleep and daytime performance when treating insomniaAlthough a 25-milligram dose of daridorexant reached the primary endpoint for improved sleep maintenance, the drug failed to significantly improve the persistent sleep incubation period (LPS)Guy Braunstein, head of global clinical development at Idorsia, said: "I am pleased to see the repeating role of 25 mg daridorexant in this large validation studyThe therapeutic effects of both studies were significant"The drugmaker said its goal is to submit regulatory documents for the compound to the Fdathe U.Saround the end of 2020